Wall Street brokerages forecast that Aldeyra Therapeutics, Inc (NASDAQ:ALDX) will report earnings per share of ($0.53) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Aldeyra Therapeutics’ earnings. The highest EPS estimate is ($0.52) and the lowest is ($0.53). Aldeyra Therapeutics posted earnings per share of ($0.52) in the same quarter last year, which would indicate a negative year over year growth rate of 1.9%. The company is scheduled to report its next quarterly earnings report on Wednesday, November 13th.
According to Zacks, analysts expect that Aldeyra Therapeutics will report full-year earnings of ($2.14) per share for the current financial year, with EPS estimates ranging from ($2.19) to ($2.07). For the next financial year, analysts forecast that the business will post earnings of ($2.07) per share, with EPS estimates ranging from ($2.42) to ($1.72). Zacks’ EPS calculations are an average based on a survey of research firms that follow Aldeyra Therapeutics.
Aldeyra Therapeutics (NASDAQ:ALDX) last released its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.51) by $0.02.
In related news, Director Richard Douglas acquired 20,000 shares of Aldeyra Therapeutics stock in a transaction dated Tuesday, September 10th. The stock was purchased at an average cost of $5.00 per share, for a total transaction of $100,000.00. Following the purchase, the director now directly owns 70,000 shares of the company’s stock, valued at approximately $350,000. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Todd C. Brady acquired 10,000 shares of Aldeyra Therapeutics stock in a transaction dated Monday, September 9th. The stock was bought at an average price of $4.89 per share, with a total value of $48,900.00. Following the completion of the purchase, the chief executive officer now directly owns 50,000 shares in the company, valued at $244,500. The disclosure for this purchase can be found here. Insiders bought a total of 52,229 shares of company stock valued at $272,567 over the last 90 days. 13.50% of the stock is currently owned by company insiders.
Several large investors have recently bought and sold shares of ALDX. Bank of America Corp DE increased its stake in shares of Aldeyra Therapeutics by 139.4% in the 4th quarter. Bank of America Corp DE now owns 12,181 shares of the biotechnology company’s stock worth $102,000 after purchasing an additional 7,093 shares in the last quarter. Deutsche Bank AG increased its stake in Aldeyra Therapeutics by 17.0% in the 4th quarter. Deutsche Bank AG now owns 39,658 shares of the biotechnology company’s stock worth $328,000 after buying an additional 5,753 shares in the last quarter. BNP Paribas Arbitrage SA purchased a new stake in Aldeyra Therapeutics in the 1st quarter worth $40,000. Rhumbline Advisers increased its stake in Aldeyra Therapeutics by 17.3% in the 1st quarter. Rhumbline Advisers now owns 27,183 shares of the biotechnology company’s stock worth $245,000 after buying an additional 4,010 shares in the last quarter. Finally, National Asset Management Inc. increased its stake in Aldeyra Therapeutics by 69.4% in the 1st quarter. National Asset Management Inc. now owns 27,006 shares of the biotechnology company’s stock worth $244,000 after buying an additional 11,066 shares in the last quarter. Hedge funds and other institutional investors own 61.26% of the company’s stock.
NASDAQ ALDX opened at $5.76 on Tuesday. The business’s fifty day moving average price is $5.11 and its 200-day moving average price is $6.74. The stock has a market capitalization of $162.44 million, a price-to-earnings ratio of -3.22 and a beta of 0.61. Aldeyra Therapeutics has a 1-year low of $4.31 and a 1-year high of $16.70.
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc, a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.